Physiology and Surgery

生理学和外科

基本信息

  • 批准号:
    8452823
  • 负责人:
  • 金额:
    $ 22.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-09-01 至
  • 项目状态:
    未结题

项目摘要

The Physiology / Surgery Core (PSC; Core C), used by all of the Projects of this PPG, will offer integrated services for assessing heart function and structure in settings that mimic cardiac pathology in mice. Accordingly, Core C will maintain equipment and provide staffing to offer Projects the following services: 1) Physiology: echocardiography, invasive hemodynamics, isolated working heart preparation, and 2) Surgery: in vivo myocardial infarction, reperfusion, transaortic constriction, and intramyocardial adoptive transfer cell injection. The PSC is centrally located in the SDSU BioScience Center, which houses the SDSU Heart Institute labs and administrative offices. The PSC is composed of fully equipped surgery and physiology suites and dedicated mouse holding rooms. PPG investigators both institutions will be able to fully utilize PSC resources with "on demand" availability of two part-time trained cardiac surgeons, a physiology technician, and a mouse husbandry specialist. All required equipment including a Visualsonics Vevo 770 and Scisense hemodynamic assessment package are in place and operational in the PSC. The PSC is under the direction of Dr. Mark Sussman, who has a legacy of publications in the techniques offered by core and is well versed in administration of such services for Program participants. Dr. Glembotski brings his decades of experience in mouse physiology and surgery as co-Director of the PSC. An additional advantage of the PSC is that it adjoins the SDSU Heart Institute Mouse Genetics Center, which facilitates the generation and use of genetically modified mice by Projects. The PSC was designed specifically to serve this multi-institutional PPG; accordingly, it will maximize collaborations between projects, thus enhancing the synergy of this integrated research program. The PSC complements and integrates with the Cell Biology / Histology Core (CBHC) by serving as the location where principles discovered using cells generated with cells from the CBHC will be assessed in a pathophysiological in vivo context that mimics cardiomyopathic conditions. The PSC will be equally used by all four Projects of the Program
生理学/外科核心(PSC;核心C),用于本PPG的所有项目,将提供综合服务,用于在模拟小鼠心脏病理的环境中评估心脏功能和结构。因此,核心C将维护设备并提供人员,以向项目提供以下服务:1)生理学:超声心动图、侵入性血流动力学、离体工作心脏准备,以及2)手术:体内心肌梗死、再灌注、经主动脉缩窄和心肌内过继转移细胞注射。PSC位于SDSU生物科学中心的中心,该中心设有SDSU心脏研究所实验室和行政办公室。PSC由设备齐全的手术室和生理室以及专用小鼠饲养室组成。PPG研究人员和两个机构将能够充分利用PSC资源,“按需”提供两名兼职训练有素的心脏外科医生、一名生理学技术人员和一名小鼠饲养专家。所有所需设备(包括Visualsonics Vevo 770和Scisense血流动力学评估包)均已到位,并在PSC中运行。PSC由Mark Sussman博士领导,他在核心技术方面有着丰富的出版物,并且精通为计划参与者提供此类服务的管理。Glembotski博士带来了他在小鼠生理学和手术方面数十年的经验,担任PSC的联合主任。PSC的另一个优势是它毗邻SDSU心脏研究所小鼠遗传学中心,该中心促进了项目转基因小鼠的产生和使用。PSC是专门为服务于这个多机构PPG而设计的;因此,它将最大限度地提高项目之间的合作,从而增强这个综合研究计划的协同作用。PSC补充并整合了细胞生物学/组织学核心(CBHC),作为使用来自CBHC的细胞产生的细胞发现的原理将在模拟心肌病状况的病理生理学体内背景下进行评估的位置。PSC将被该计划的所有四个项目平等使用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK ALAN SUSSMAN其他文献

MARK ALAN SUSSMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK ALAN SUSSMAN', 18)}}的其他基金

Next Generation Regenerative Therapy with Pim-1 Enhanced Cardiac Progenitor Cells
使用 Pim-1 增强型心脏祖细胞的下一代再生疗法
  • 批准号:
    9352458
  • 财政年份:
    2017
  • 资助金额:
    $ 22.52万
  • 项目类别:
Enhanced Myocardial Repair with CardioClusters and CardioChimeras
利用 CardioClusters 和 CardioChimeras 增强心肌修复
  • 批准号:
    8675146
  • 财政年份:
    2014
  • 资助金额:
    $ 22.52万
  • 项目类别:
Enhanced Myocardial Repair with CardioClusters and CardioChimeras
利用 CardioClusters 和 CardioChimeras 增强心肌修复
  • 批准号:
    9266810
  • 财政年份:
    2014
  • 资助金额:
    $ 22.52万
  • 项目类别:
Enhanced Myocardial Repair with CardioClusters and CardioChimeras
利用 CardioClusters 和 CardioChimeras 增强心肌修复
  • 批准号:
    9041013
  • 财政年份:
    2014
  • 资助金额:
    $ 22.52万
  • 项目类别:
Beta-adrenergic signaling: double edged sword of myocardial repair
β-肾上腺素能信号传导:心肌修复的双刃剑
  • 批准号:
    8431986
  • 财政年份:
    2013
  • 资助金额:
    $ 22.52万
  • 项目类别:
Beta-adrenergic signaling: double edged sword of myocardial repair
β-肾上腺素能信号传导:心肌修复的双刃剑
  • 批准号:
    8790766
  • 财政年份:
    2013
  • 资助金额:
    $ 22.52万
  • 项目类别:
Cardioprotection by optimizing mTOR activity
通过优化 mTOR 活性来保护心脏
  • 批准号:
    8446101
  • 财政年份:
    2013
  • 资助金额:
    $ 22.52万
  • 项目类别:
Cardioprotection by optimizing mTOR activity
通过优化 mTOR 活性来保护心脏
  • 批准号:
    8792404
  • 财政年份:
    2013
  • 资助金额:
    $ 22.52万
  • 项目类别:
Beta-adrenergic signaling: double edged sword of myocardial repair
β-肾上腺素能信号传导:心肌修复的双刃剑
  • 批准号:
    8996702
  • 财政年份:
    2013
  • 资助金额:
    $ 22.52万
  • 项目类别:
Cardioprotection by optimizing mTOR activity
通过优化 mTOR 活性来保护心脏
  • 批准号:
    8620713
  • 财政年份:
    2013
  • 资助金额:
    $ 22.52万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 22.52万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 22.52万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 22.52万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 22.52万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 22.52万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 22.52万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 22.52万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 22.52万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 22.52万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 22.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了